Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Jerald P. Radich, MD, Andreas Hochhaus, MD, Francis J. Giles, MD FRCPI, FRCPath, David M. Ross, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Dong-Wook Kim, Rafik Fellague-Chebra, MD, Manu Sondhi, MD PhD, Ranjan Tiwari, MSc, Kaushal Mishra, PhD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 2932.

https://doi.org/10.1182/blood-2019-129393

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Blood (2018) 132 (Supplement 1): 688.

https://doi.org/10.1182/blood-2018-99-110381

Published: 2018

Journal Articles

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Filippo Spriano, Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Gaetanina Golino, Luciano Cascione, PhD, Emanuele Zucca, Anastasios Stathis, MD, Francis J. Giles, MD FRCPI, FRCPath, Francesco Bertoni, MD

Blood (2018) 132 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2018-99-114900

Published: 2018

Journal Articles

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Giuseppe Saglio, MD PhD, Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 1598.

https://doi.org/10.1182/blood.V130.Suppl_1.1598.1598

Published: 2017

Journal Articles

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Markus Pfirrmann, Francois-Xavier Mahon, MD PhD, Joelle Guilhot, PhD, Johan Richter, MD PhD, Francis J. Giles, MD MB, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Giuseppe Saglio, MD PhD, Weiping Deng, Darshan Dalal, MPH, MD PhD, Susanne Saussele, MD

Blood (2017) 130 (Supplement 1): 1601.

https://doi.org/10.1182/blood.V130.Suppl_1.1601.1601

Published: 2017

Journal Articles

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francois-Xavier Mahon, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Giuseppe Saglio, MD PhD

Blood (2017) 130 (Supplement 1): 2878.

https://doi.org/10.1182/blood.V130.Suppl_1.2878.2878

Published: 2017

Journal Articles

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Blood (2017) 130 (Supplement 1): 1631.

https://doi.org/10.1182/blood.V130.Suppl_1.1631.1631

Published: 2017

Journal Articles

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Adam M. Petrich, MD, Leo I. Gordon, MD, Jeffrey R. Infante, MD, Sumit Madan, MD, Francis J. Giles, MD, Halla S. Nimeiri, MBBS, Jason B. Kaplan, MD, Kate Stumpo, Bin Zhang, ScD, Stephanie Faucette, PharmD, PhD, Yaping Shou, MD PhD, Kent C. Shih, MD

Blood (2015) 126 (23): 2693.

https://doi.org/10.1182/blood.V126.23.2693.2693

Published: 2015

Journal Articles

MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia.

Ronan T. Swords, M.D., Kevin R. Kelly, MD, Peter G. Smith, PhD, James J. Gansey, Devalingam Mahalingam, M.D., Swaminathan Padmanabhan, MD, MBBS, Michael C. O'Dwyer, MD, FRCPI, FRCPath, Steffan T. Nawrocki, PhD, Francis J. Giles, MD, Jennifer S. Carew, Ph.D.

Blood (2009) 114 (22): 1021.

https://doi.org/10.1182/blood.V114.22.1021.1021

Published: 2009

Journal Articles

Adenosine A2A and Beta-2 Adrenergic Receptor Agonism: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Richard J. Rickles, Ph.D., Laura Pierce, Thomas Giordano, Winnie F. Tam, Ph.D., William Avery, Melissa Farwell, David Crowe, Mei Chen, Ph.D., Alexander Brown, Vikram Kansra, PhD, Steffan T. Nawrocki, PhD, Jennifer S Carew, Ph.D., Francis J Giles, MD, Margaret S Lee, PhD

Blood (2008) 112 (11): 384.

https://doi.org/10.1182/blood.V112.11.384.384

Published: 2008

Journal Articles

Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program

Philipp D. le Coutre, MD, Michael O’Dwyer, MD, FRCPI, FRCPath, Tomasz Szczudlo, MD, Richard C. Woodman, MD, Francis J. Giles, MD

Blood (2008) 112 (11): 4271.

https://doi.org/10.1182/blood.V112.11.4271.4271

Published: 2008

Journal Articles

Myelodysplastic Syndromes and Acute Myeloid Leukemia with t(6;9)(p23;q34).

John Delmonte, Jr., MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Francis J. Giles, MD, Lynne Abruzzo, MD, Sherry Pierce, Jorge Cortes, MD

Blood (2007) 110 (11): 3502.

https://doi.org/10.1182/blood.V110.11.3502.3502

Published: 2007

Journal Articles

A Phase 1 Dose-Escalation Study of the Novel Cell Cycle Active Agent SNS-595 in Advanced Leukemias.

Jeffrey E. Lancet, MD, Judith E. Karp, MD, Nancy Havrilla, Ute Hoch, PhD, Jeffrey Silverman, PhD, Daniel Adelman, MD, Francis J. Giles, MD

Blood (2006) 108 (11): 1962.

https://doi.org/10.1182/blood.V108.11.1962.1962

Published: 2006

Journal Articles

The Predictive Value of a “Positive” ASH Abstract in AML Therapeutics.

Elihu H. Estey, MD, Slyva H. Bedikian, MS, Dianne C. Witter, Sherry A. Pierce, BA, Francis J. Giles, MD

Blood (2006) 108 (11): 1964.

https://doi.org/10.1182/blood.V108.11.1964.1964

Published: 2006

Journal Articles

Phase I Study of XL-119, a Rebeccamycin Analog, in Patients with Refractory Hematological Malignancies.

Francis J. Giles, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Zeev Estrov, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Deborah Thomas, MD, William Wierda, MD, Srdan Verstovsek, MD

Blood (2006) 108 (11): 1969.

https://doi.org/10.1182/blood.V108.11.1969.1969

Published: 2006

Journal Articles

Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.

Gloria N. Mattiuzzi, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Maria E. Cabanillas, MD, Francis J. Giles, MD, Susan O’Brien, MD, Guillermo Garcia-Manero, MD, Hagop H. Kantarjian, MD

Blood (2006) 108 (11): 4483.

https://doi.org/10.1182/blood.V108.11.4483.4483

Published: 2006

Journal Articles

PTK787/ZK 222584 (PTK/ZK), an Oral Tyrosine Kinase Inhibitor, Has Activity in Patients with Agnogenic Myeloid Metaplasia (AMM).

Francis J. Giles, MD, Michael Carroll, MD, Alan List, MD, Alessandra Ferrajoli, MD, Deborah Thomas, MD, Jorge Cortes, MD, Eric Feldman, MD, Gail Roboz, MD

Blood (2006) 108 (11): 4920.

https://doi.org/10.1182/blood.V108.11.4920.4920

Published: 2006

Journal Articles

Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) ≥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).

Stefan Faderl, MD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Deborah A. Thomas, MD, Susan O’Brien, MD, Srdan Verstovsek, MD, PhD, William Wierda, MD, PhD, Jorge Cortes, MD, Francis J. Giles, MD, Monica Kwari, R.N., Rita Jarmon, R.N., Hagop M. Kantarjian, MD

Blood (2005) 106 (11): 2804.

https://doi.org/10.1182/blood.V106.11.2804.2804

Published: 2005

NARROW

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia.

Adenosine A2A and Beta-2 Adrenergic Receptor Agonism: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program

Myelodysplastic Syndromes and Acute Myeloid Leukemia with t(6;9)(p23;q34).

A Phase 1 Dose-Escalation Study of the Novel Cell Cycle Active Agent SNS-595 in Advanced Leukemias.

The Predictive Value of a “Positive” ASH Abstract in AML Therapeutics.

Phase I Study of XL-119, a Rebeccamycin Analog, in Patients with Refractory Hematological Malignancies.

Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.

PTK787/ZK 222584 (PTK/ZK), an Oral Tyrosine Kinase Inhibitor, Has Activity in Patients with Agnogenic Myeloid Metaplasia (AMM).

Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) ≥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only